Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy ... of its experimental obesity drug CagriSema, which only showed a 22.7% weight ...

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") of a class action securities lawsuit.

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

For the final quarter of 2024, the fund returned -5.12%, outpacing the -7.58% result of the benchmark MSCI All Country World ...

In 2023, the agency approved tirzepatide under the brand name Zepbound for weight ... Last December, Novo Nordisk revealed phase 3 results for cagrisema, a combination of semaglutide and an ...